Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.COV2.S and NVX-CoV2373 booster study in African adolescents and adults with and without HIV
PACTR202203582920839Phase 2Recruiting
- Sponsor
- Victoria Biomedical Research Institute
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ad26.COV2.S booster arm with NVX-CoV2373 booster arm (2 arms). Started Apr 2022; status: recruiting.
02
Drugs
Ad26.COV2.SNVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202203582920839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202203582920839.